Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BDM-2 in Healthy Males
NCT03634085Phase 1Completed
- Sponsor
- Hivih
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BDM-2 in human immunodeficiency virus infection (HIV) (2 cohorts), sponsored by Hivih. Primary endpoint: Number of Treatment Related Adverse Event, Including Abnormal Laboratory Events up to 4 months. Started May 2018; status: completed.
02
Drugs
BDM-2
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03634085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634085.